Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for HST Global Inc. (HSTC : OTC)

• Company Description    HST GLOBAL, INC., formerly NT Holding Corp., is in the business of developing drugs to combat cancer. HSTI is a development-stage biopharmaceutical company that acquires and develops products for the treatment of cancer. The Company has focused on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer, and then developing those drug candidates for commercial use. The Company has entered into a letter of intent for the rights to one clinical stage drug candidate: Salicinium. Salicinium is an oral and parental active inhibitor. Clinical studies demonstrate that Salicinium alters malignant cell fermentation dynamics, blocks cell division (mitosis) and causes fermenting (cancer) cells' loss of ability to withstand the innate immune reactions. Number of Employees: 1

• Price / Volume Information    Yesterday's Closing Price: $0.28 Daily Weekly Monthly 20 Day Moving Average: 213 shares Shares Outstanding: 57.77 (millions) Market Capitalization: $15.89 (millions) Beta: -1.24 52 Week High: $1.10 52 Week Low: $0.27 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -46.29% -48.30% 12 Week -48.36% -56.56% Year To Date -67.65% -69.70%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 509 OLD GREAT NECK ROAD SUITE 105 - VIRGINIA BEACH,VA 23454 USA ph: 800-961-4750 fax: - None http://www.hstglobal.com

• General Corporate Information    Officers Ron Howell - Chief Executive Officer Wesley D. Tate - Chief Financial Officer Dr. James Forsythe - Director - - - - - - Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 40432E202 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/24 Next Expected EPS Date: 08/25/25 Share - Related Items Shares Outstanding: 57.77 Most Recent Split Date: 11.00 (0.07:1) Beta: -1.24 Market Capitalization: $15.89 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/25/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 9.72 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 100.00% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - - 12/31/24 - - Current Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - - Quick Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - - Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - - 12/31/24 - - Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©